WO2002044130A1 - Dérivés d'acide carboxylique substitués - Google Patents

Dérivés d'acide carboxylique substitués Download PDF

Info

Publication number
WO2002044130A1
WO2002044130A1 PCT/JP2001/010353 JP0110353W WO0244130A1 WO 2002044130 A1 WO2002044130 A1 WO 2002044130A1 JP 0110353 W JP0110353 W JP 0110353W WO 0244130 A1 WO0244130 A1 WO 0244130A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid derivatives
substituted carboxylic
same
drugs
Prior art date
Application number
PCT/JP2001/010353
Other languages
English (en)
Japanese (ja)
Inventor
Hiroyuki Miyachi
Masahiro Nomura
Yukie Takahashi
Takahiro Tanase
Kouji Murakami
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to AU2002222550A priority Critical patent/AU2002222550A1/en
Priority to JP2002546500A priority patent/JPWO2002044130A1/ja
Publication of WO2002044130A1 publication Critical patent/WO2002044130A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouveaux dérivés d'acide carboxylique substitués qui se lient au récepteur activé proliférateur du péroxysome α humain (PPARα) en tant que ligand dudit récepteur et qui activent ce récepteur. Lesdits dérivés sont donc efficaces en tant que médicaments contre des maladies du métabolisme, tels que des hypolipidémiants (en particulier dans le foie), en tant que médicaments contre l'aggravation de l'artériosclérose et en tant que médicaments contre l'obésité et contre le diabète. La présente invention concerne également un procédé de production desdits médicaments. Ces nouveaux dérivés sont représentés par la formule générale (1). La présente invention concerne encore des esters, des sels pharmaceutiquement acceptables et des hydrates desdits dérivés. Dans ladite formule, R1 représente hydrogène, halogéno, hydroxy, 2-phényléthyle, 2-phényléthoxy, hydroxyphénoxy ou benzyloxyphénoxy et R2 représente alkyle inférieur C¿1-4?. La présente invention concerne également un procédé de production de ces composés.
PCT/JP2001/010353 2000-11-29 2001-11-28 Dérivés d'acide carboxylique substitués WO2002044130A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002222550A AU2002222550A1 (en) 2000-11-29 2001-11-28 Substituted carboxylic acid derivatives
JP2002546500A JPWO2002044130A1 (ja) 2000-11-29 2001-11-28 置換カルボン酸誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-363677 2000-11-29
JP2000363677 2000-11-29

Publications (1)

Publication Number Publication Date
WO2002044130A1 true WO2002044130A1 (fr) 2002-06-06

Family

ID=18834748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010353 WO2002044130A1 (fr) 2000-11-29 2001-11-28 Dérivés d'acide carboxylique substitués

Country Status (3)

Country Link
JP (1) JPWO2002044130A1 (fr)
AU (1) AU2002222550A1 (fr)
WO (1) WO2002044130A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051821A1 (fr) * 2001-12-19 2003-06-26 Astrazeneca Ab Derives substitues de l'acide phenylpropionique comme agonistes au recepteur alpha active par proliferateur de peroxysome humain
WO2005009942A1 (fr) * 2003-07-28 2005-02-03 Kyorin Pharmaceutical Co., Ltd. Derive d'acide phenylpropionique substitue optiquement actif
FR2875805A1 (fr) * 2004-09-27 2006-03-31 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
JP2006512334A (ja) * 2002-12-10 2006-04-13 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
WO2006105304A2 (fr) * 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Modulateurs lta4h de phenyle et pyridyle
JP2007001912A (ja) * 2005-06-22 2007-01-11 Univ Of Tokyo 置換フェニルプロピオン酸誘導体
US7462644B2 (en) 2002-12-21 2008-12-09 Astrazeneca Ab Therapeutic agents
US7488844B2 (en) 2001-12-19 2009-02-10 Astrazeneca Ab Therapeutic agents
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
WO2000075103A1 (fr) * 1999-06-09 2000-12-14 Kyorin Pharmaceutical Co., Ltd. DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a)
WO2001025181A1 (fr) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Derives d'acide carboxylique et medicaments les contenant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
WO2000075103A1 (fr) * 1999-06-09 2000-12-14 Kyorin Pharmaceutical Co., Ltd. DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a)
WO2001025181A1 (fr) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Derives d'acide carboxylique et medicaments les contenant

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256307B2 (en) 2001-12-19 2007-08-14 Astrazeneca Ab Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α(PPAR)
WO2003051822A1 (fr) * 2001-12-19 2003-06-26 Astrazeneca Ab Derives d'acide phenylpropionique comme antagonistes de recepteur alpha active par proliferateur de peroxisome humain (ppar)
US7514471B2 (en) 2001-12-19 2009-04-07 Astrazeneca Ab Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR)
WO2003051821A1 (fr) * 2001-12-19 2003-06-26 Astrazeneca Ab Derives substitues de l'acide phenylpropionique comme agonistes au recepteur alpha active par proliferateur de peroxysome humain
US7488844B2 (en) 2001-12-19 2009-02-10 Astrazeneca Ab Therapeutic agents
JP2006512334A (ja) * 2002-12-10 2006-04-13 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
US7462644B2 (en) 2002-12-21 2008-12-09 Astrazeneca Ab Therapeutic agents
WO2005009942A1 (fr) * 2003-07-28 2005-02-03 Kyorin Pharmaceutical Co., Ltd. Derive d'acide phenylpropionique substitue optiquement actif
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative
WO2006035157A3 (fr) * 2004-09-27 2006-06-29 Genfit Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
WO2006035157A2 (fr) * 2004-09-27 2006-04-06 Genfit Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
FR2875805A1 (fr) * 2004-09-27 2006-03-31 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
WO2006105304A3 (fr) * 2005-03-31 2007-04-05 Janssen Pharmaceutica Nv Modulateurs lta4h de phenyle et pyridyle
WO2006105304A2 (fr) * 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Modulateurs lta4h de phenyle et pyridyle
JP2007001912A (ja) * 2005-06-22 2007-01-11 Univ Of Tokyo 置換フェニルプロピオン酸誘導体

Also Published As

Publication number Publication date
AU2002222550A1 (en) 2002-06-11
JPWO2002044130A1 (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
RU2676694C2 (ru) Заболевания, связанные с токсичным альдегидом, и их лечение
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
PL361807A1 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments
CA2690841A1 (fr) Composition, procede et preparation d'acide biliaire synthetique
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
CN1938028A (zh) 止痒剂
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
CN102159537A (zh) 应用于细菌感染治疗的有机化合物
HUT69723A (en) Substituted salicylic acid derivatives, process for producing them and use of them
AU2002347906A2 (en) Treatment of CNS disorders using CNS target modulators
WO2002044130A1 (fr) Dérivés d'acide carboxylique substitués
ATE522513T1 (de) N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
NZ516290A (en) Substituted phenoxyacetic acids
TW200507836A (en) Therapeutic agents
JP2019077695A (ja) オキシモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、プロドラッグ、その製造法及び使用
WO2002044127A1 (fr) Dérivés d'acide carboxylique substitué
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
MY135821A (en) Therapeutic agents
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists
JP3177607B2 (ja) 新規な二芳香族ジベンゾフラン誘導体およびそれらのヒトまたは動物用医薬品および化粧品への用途
IL91382A (en) Dicitons are converted into alkanyl or ethylmethylene, through their preparation and pharmaceutical preparations containing them
WO2009027482A3 (fr) Composés de tétrahydroquinoline antagonisant le récepteur de la tsh
TW593294B (en) Polycyclic thiazole systems having anorectic activity, processes for their preparation and pharmaceutical composition comprising these compounds
WO2006050241A1 (fr) Antagonistes ep4 de la prostaglandine
WO2002044131A1 (fr) Dérivés d'acide carboxylique substitués

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002546500

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase